

Christoph J Stephan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8989718/publications.pdf>

Version: 2024-02-01

110
papers

3,449
citations

159585

30
h-index

155660

55
g-index

118
all docs

118
docs citations

118
times ranked

5492
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	9.1	345
2	All-cause mortality in treated HIV-infected adults with CD4 $\geq 500/\text{mm}^3$ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	1.9	217
3	Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. <i>Lancet</i> , The, 2015, 385, 1428-1435.	13.7	199
4	Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. <i>Lancet</i> , The, 2015, 385, 1098-1106.	13.7	170
5	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, e8-e16.	2.1	142
6	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for ≥ 3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
7	Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. <i>Clinical Infectious Diseases</i> , 2017, 65, 855-859.	5.8	101
8	Is It Safe to Discontinue Primary <i>Pneumocystis jirovecii</i> Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count ≥ 200 Cells/ μL ? <i>Clinical Infectious Diseases</i> , 2010, 51, 611-619.	5.8	96
9	Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. <i>Aids</i> , 2008, 22, 2471-2479.	2.2	90
10	Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. <i>Aids</i> , 2018, 32, 2405-2416.	2.2	83
11	New Lineage of Lassa Virus, Togo, 2016. <i>Emerging Infectious Diseases</i> , 2018, 24, 599-602.	4.3	79
12	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	5.8	75
13	Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e68152.	2.5	75
14	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. <i>Aids</i> , 2013, 27, 803-813.	2.2	70
15	Presence of <i>Chlamydia pneumoniae</i> DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 585-589.	5.3	65
16	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 56-61.	4.0	65
17	Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , 2008, 22, 2279-2289.	2.2	64
18	Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1-Infected Patients. <i>Clinical Infectious Diseases</i> , 2011, 52, 122-127.	5.8	64

#	ARTICLE	IF	CITATIONS
19	Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. <i>Aids</i> , 2010, 24, F31-F35.	2.2	61
20	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1571-1577.	5.8	52
21	Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. <i>Journal of Electrocardiology</i> , 2011, 44, 779-785.	0.9	47
22	Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. <i>Aids</i> , 2004, 18, 503-508.	2.2	46
23	The Management of Needlestick Injuries. <i>Deutsches Arzteblatt International</i> , 2013, 110, 61-7.	0.9	45
24	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	5.8	44
25	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	1.9	43
26	Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 1087-1093.	3.0	40
27	Needlestick injuries: causes, preventability and psychological impact. <i>Infection</i> , 2014, 42, 549-52.	4.7	40
28	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	4.7	35
29	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	5.8	34
30	The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1024-1030.	3.0	31
31	Colonization with multidrug-resistant organisms is associated with increased mortality in liver transplant candidates. <i>PLoS ONE</i> , 2021, 16, e0245091.	2.5	29
32	Antibody response to SARS-CoV-2 for more than one year—Kinetics and persistence of detection are predominantly determined by avidity progression and test design. <i>Journal of Clinical Virology</i> , 2022, 146, 105052.	3.1	29
33	Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 520-522.	1.5	26
34	Cryptococcosis due to <i>Cryptococcus gattii</i> in Germany from 2004–2013. <i>International Journal of Medical Microbiology</i> , 2015, 305, 719-723.	3.6	26
35	Myocardial Fibrosis and Inflammation by CMR Predict Cardiovascular Outcome in People Living With HIV. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1548-1557.	5.3	26
36	Renal AA-amyloidosis in intravenous drug users – a role for HIV-infection?. <i>BMC Nephrology</i> , 2012, 13, 151.	1.8	25

#	ARTICLE	IF	CITATIONS
37	Impact of baseline HIV RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials. HIV Medicine, 2013, 14, 284-292.	2.2	25
38	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 292-300.	2.1	24
39	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 240-250.	2.1	24
40	The role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses. BMC Infectious Diseases, 2017, 17, 450.	2.9	23
41	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	5.8	20
42	Pharmacokinetics, Safety and Efficacy of Saquinavir/ Ritonavir 1,000/100 Mg Twice Daily as HIV Type-1 Therapy and Transmission Prophylaxis in Pregnancy. Antiviral Therapy, 2008, 13, 1039-1046.	1.0	20
43	Travel-Acquired Dengue Infection: Clinical Spectrum and Diagnostic Aspects. Infection, 2002, 30, 225-228.	4.7	18
44	Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study. PLoS ONE, 2013, 8, e56249.	2.5	18
45	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clinical Infectious Diseases, 2021, 73, 50-59.	5.8	18
46	Not Recommended, But Done: Breastfeeding with HIV in Germany. AIDS Patient Care and STDs, 2021, 35, 33-38.	2.5	17
47	Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). AIDS Research and Therapy, 2019, 16, 34.	1.7	16
48	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e2323-e2333.	5.8	16
49	Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects. Journal of Intensive Care, 2015, 3, 31.	2.9	15
50	Cytokine and Chemokine Signature in Elite Versus Viremic Controllers Infected with HIV. AIDS Research and Human Retroviruses, 2016, 32, 579-587.	1.1	15
51	Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology, 2019, 69, 1135-1150.	7.3	15
52	Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naïve HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 283-289.	2.1	14
53	CD4 ⁺ T cell lymphopenia predicts mortality from Pneumocystis pneumonia in kidney transplant patients. Clinical Transplantation, 2020, 34, e13877.	1.6	13
54	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	2.1	13

#	ARTICLE	IF	CITATIONS
55	HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy. <i>Medical Microbiology and Immunology</i> , 2016, 205, 575-583.	4.8	12
56	Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. <i>Clinical Infectious Diseases</i> , 2022, 75, 786-794.	5.8	12
57	Research Letter. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, e73-e75.	2.1	11
58	Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients. <i>Vaccine Journal</i> , 2014, 21, 867-876.	3.1	11
59	Elevated prevalence of multidrug-resistant gram-negative organisms in HIV positive men. <i>BMC Infectious Diseases</i> , 2017, 17, 206.	2.9	11
60	Quadruple Nucleos(t)ide Reverse Transcriptase Inhibitors-Only Regimen of Tenofovir Plus Zidovudine/Lamivudine/Abacavir in Heavily Pre-Treated HIV-1 Infected Patients: Salvage Therapy or Backbone Only?. <i>Current HIV Research</i> , 2009, 7, 320-326.	0.5	10
61	Immune Response after a Single Dose of the 2010/11 Trivalent, Seasonal Influenza Vaccine in HIV-1 Infected Patients and Healthy Controls. <i>HIV Clinical Trials</i> , 2013, 14, 175-184.	2.0	10
62	Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2809-2818.	3.0	10
63	Dose reduction effective in alleviating symptoms of saquinavir toxicity. <i>International Journal of STD and AIDS</i> , 2007, 18, 81-84.	1.1	9
64	Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017. <i>Infection</i> , 2020, 48, 723-733.	4.7	9
65	Reasons for Choice of Antiretroviral Regimens in HIV Patients Presenting Late for Initial Treatment in Europe. <i>AIDS Patient Care and STDs</i> , 2021, 35, 110-115.	2.5	9
66	High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis. <i>Journal of Infection</i> , 2022, 84, 8-16.	3.3	9
67	Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 375-381.	1.9	8
68	Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 365-374.	1.1	8
69	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	5.8	8
70	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/μL. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	3.0	8
71	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	8
72	Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R. <i>Journal of Infection</i> , 2010, 61, 346-350.	3.3	7

#	ARTICLE	IF	CITATIONS
73	Comparison of Drug Resistance Scores for Tipranavir in Protease Inhibitor-Naïve Patients Infected with HIV-1 B and Non-B Subtypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5362-5366.	3.2	7
74	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	4.0	7
75	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project. <i>BMC Infectious Diseases</i> , 2016, 16, 654.	2.9	7
76	Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2273-2275.	3.2	6
77	Experience with tenofovir disoproxil fumarate for antiretroviral therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1197-1209.	1.8	6
78	HIV-associated lung cancer: Survival in an unselected cohort. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 766-772.	1.5	6
79	Autologous stem cell transplantation in HIV-related lymphoma in the rituximab era - a feasibility study in a monocentric cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19648.	3.0	5
80	Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis. <i>Medical Microbiology and Immunology</i> , 2014, 203, 409-414.	4.8	5
81	Disseminated disease due to non-tuberculous mycobacteria in HIV positive patients: A retrospective case control study. <i>PLoS ONE</i> , 2021, 16, e0254607.	2.5	5
82	Winterbottom's Sign and Hypertrophic Cardiomyopathy. <i>Scandinavian Journal of Infectious Diseases</i> , 2002, 34, 544-545.	1.5	4
83	Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy. <i>HIV Medicine</i> , 2014, 15, 124-128.	2.2	4
84	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	3.0	4
85	Species distribution and clinical features of infection and colonisation with non-tuberculous mycobacteria in a tertiary care centre, central Germany, 2006-2016. <i>Infection</i> , 2019, 47, 817-825.	4.7	4
86	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	2.2	4
87	Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy. <i>Medical Microbiology and Immunology</i> , 2013, 202, 117-124.	4.8	3
88	Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 656-659.	1.5	3
89	Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD). <i>Medical Microbiology and Immunology</i> , 2016, 205, 315-320.	4.8	3
90	Ischemic stroke in human immunodeficiency virus-positive patients: An increasingly age-related comorbidity?. <i>European Stroke Journal</i> , 2020, 5, 252-261.	5.5	3

#	ARTICLE	IF	CITATIONS
91	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 248-257.	2.1	3
92	Influence of tenofovir exposure in utero on primary dentition. <i>European Journal of Pediatrics</i> , 2020, 179, 1761-1768.	2.7	3
93	Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2355-2367.	1.8	2
94	144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19770.	3.0	2
95	Proton ¹ H- and Phosphorus ³¹ P-MR spectroscopy (MRS) in asymptomatic HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19577.	3.0	2
96	Performance of the Abbott RealTime HIV-1 assay versus the Roche Amplicor HIV-1 Monitor™ Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1708-1710.	3.0	2
97	Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 192-201.	2.0	2
98	Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection. <i>Virology</i> , 2015, 485, 213-222.	2.4	2
99	Rapid regression of Kaposi's sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixed-dose antiretroviral combination therapy. <i>Infection</i> , 2016, 44, 103-106.	4.7	2
100	Risk factors for IRIS in HIV-associated Pneumocystis-pneumonia following ART initiation. <i>Journal of Infection</i> , 2021, 83, 347-353.	3.3	2
101	Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients. <i>European Journal of Medical Research</i> , 2010, 15, 369.	2.2	1
102	Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001-2018. <i>Emerging Infectious Diseases</i> , 2020, 26, 2439-2443.	4.3	1
103	Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II Study. <i>HIV/AIDS - Research and Palliative Care</i> , 2021, Volume 13, 789-800.	0.8	1
104	Phenotypic Diversity of <i>Cryptococcus neoformans</i> var. <i>neoformans</i> Clinical Isolates from Localized and Disseminated Infections. <i>Microorganisms</i> , 2022, 10, 321.	3.6	1
105	Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient. <i>Aids</i> , 2004, 18, 1613-1614.	2.2	0
106	Comparison of Roche Amplicor Ultrasensitive and Abbott RealTime assays for samples with low or undetectable HIV RNA levels. <i>Aids</i> , 2012, 26, 1580-1581.	2.2	0
107	Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens. <i>Journal of the International AIDS Society</i> , 2014, 17, 19720.	3.0	0
108	Three Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naïve Volunteers Infected With HIV-1. <i>Annals of Internal Medicine</i> , 2015, 162, 460-461.	3.9	0

#	ARTICLE	IF	CITATIONS
109	P045â€¦Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults. Sexually Transmitted Infections, 2016, 92, A34.1-A34.	1.9	0
110	HLAâ€¢57.01 shields people living with HIV for significantly better periodontal health. Journal of Periodontology, 2018, 89, 966-972.	3.4	0